Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
- First efficacy data from the clinical trial with HDP-101 in multiple myeloma
- Expansion of the ADC technology platform to include further payloads
- New Management Board team
- Successful financing activities; sales revenue and other income above plan
- Conference call to be held on 25 March 2024 at 03:00 pm CET/ 10:00 am EDT
Ladenburg, Germany, 25 March 2024 – Heidelberg Pharma AG (FSE: HPHA) today published its financial results and Annual Report for fiscal year 2023 (1 December 2022 – 30 November 2023) and its outlook for 2024.
